Ann Rheum Dis

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 26 February 2007. doi:10.1136/ard.2006.067629
Annals of the Rheumatic Diseases 2007;66:704-705
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ard.2006.067629v1
66/5/704    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prince, F. H M
Right arrow Articles by van Suijlekom-Smit, L. W A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prince, F. H M
Right arrow Articles by van Suijlekom-Smit, L. W A

LETTER

Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study

Femke H M Prince , Marinka Twilt , Nelleke C J A Jansen-Wijngaarden , Lisette W A van Suijlekom-Smit

Department of Paediatrics, Erasmus MC Sophia Children’s Hospital, Rotterdam, The Netherlands

Correspondence to:
Correspondence to:
F H M Prince
Department of Paediatrics, Sp 1545, Erasmus MC Sophia Children’s Hospital, PO Box 2060, 3000 CB Rotterdam, The Netherlands

Accepted 19 February 2007

Keywords: juvenile idiopathic arthritis; etanercept; once weekly; double dose

The first 150 words of the full text of this article appear below.

Etanercept is effective in juvenile idiopathic arthritis (JIA).1–3 Currently it is administered subcutaneously at a dose of 0.4 mg/kg (maximum of 25 mg) twice a week. Clinical trials in adults show that administration of a double dose once a week is effective enough to induce and retain remission.4,5 A pharmacokinetic model developed by Yim et al6 indicates that the same dosing regimen could be used in children. Wallace7 mentions the once weekly double dose in patients with JIA, but this is not supported by clinical trials. Therefore we evaluated the efficacy of etanercept administered subcutaneously once a week at a dose of 0.8 mg/kg (maximum of 50 mg) to retain and induce remission in patients with JIA.

Eleven patients with JIA, in remission, who had already been treated with etanercept twice a week at the usual dose were switched to the double dose of 0.8 mg/kg subcutaneously once a week. . . . [Full text of this article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism